A 45-year-old man presents to his primary care physician for a wellness checkup. He states that he feels fatigued at times but feels near his baseline. The patient smokes 1 pack of cigarettes per day, drinks alcohol occasionally, and has a past medical history of poorly controlled diabetes. His temperature is 98.6°F (37.0°C), blood pressure is 167/108 mmHg, pulse is 80/min, respirations are 10/min, and oxygen saturation is 98% on room air. Physical exam reveals an overweight man with a ruddy complexion. Bilateral gynecomastia is noted for which the patient inquires about cosmetic surgery as a treatment. Laboratory values are ordered as seen below.
Hemoglobin: 14 g/dL
Hematocrit: 42%
Leukocyte count: 6,500/mm³ with normal differential
Platelet count: 185,000/mm³
Serum:
Na+: 142 mEq/L
Cl-: 102 mEq/L
K+: 3.2 mEq/L
HCO3-: 31 mEq/L
BUN: 27 mg/dL
Glucose: 173 mg/dL
Creatinine: 1.5 mg/dL
Ca2+: 9.8 mg/dL
A CT scan demonstrates bilateral abnormal adrenal masses. What is the most appropriate initial treatment?
Q122
A 47-year-old woman comes to the physician for a follow-up examination. She has type 1 diabetes mellitus, end-stage renal disease, and was recently started on erythropoietin for anemia. Her last hemodialysis session was yesterday. Current medications also include insulin, calcitriol, and sevelamer. She appears well. Her pulse is 68/min and regular, respirations are 12/min, and blood pressure is 169/108 mm Hg. Her blood pressure was normal at previous visits. Examination shows normal heart sounds. There are no carotid, femoral, or abdominal bruits. The lungs are clear to auscultation. Laboratory studies show a hemoglobin concentration of 12 g/dL, a serum creatinine concentration of 3.4 mg/dL, and BUN of 20 mg/dL. Which of the following is the most likely cause of this patient's hypertension?
Q123
A 35-year-old woman presents to the emergency department with swelling of her face and abdominal pain. She states she was outside doing yard work when her symptoms began. The patient has a past medical history of recently diagnosed diabetes and hypertension. Her current medications include lisinopril, metformin, and glipizide. Her temperature is 99.5°F (37.5°C), blood pressure is 149/95 mmHg, pulse is 90/min, respirations are 15/min, and oxygen saturation is 99% on room air. On physical exam, the patient's cardiac and pulmonary exam are within normal limits. Dermatologic exam reveals edema of her hands, lips, and eyelids. There is mild laryngeal edema; however, the patient is speaking clearly and maintaining her airway. Which of the following is appropriate long-term management of this patient?
Q124
A 64-year-old gentleman with hypertension is started on a new diuretic medication by his primary care physician because of poor blood pressure control on his previous regimen. Before starting, he is warned by his physician that the new medication may have side effects including hypokalemia and metabolic alkalosis. Furthermore it may cause alterations in his metabolites such as hyperglycemia, hyperlipidemia, hyperuricemia, and hypercalcemia. What is the mechanism of the class of diuretic most likely being recommended by the physician?
Q125
A 68-year-old man presents to the clinic for a regular health checkup. He is hypertensive and was diagnosed with congestive heart failure last year. He has hyperlipidemia but does not take any medication for it. Although he takes his antihypertensive medications regularly, his blood pressure recordings at home tend to range between 150/98 and 160/90 mm Hg. Today, his blood pressure is 147/96 mm Hg. The doctor decides to add indapamide to his medication list and asks the patient to follow up within 2 weeks. The patient is compliant with the medication. He comes back to the physician in just one week complaining of muscle cramping and weakness. Which of the following is the most likely cause of his symptoms?
Q126
A 58-year-old man presents with a sudden-onset severe headache and vomiting for the past 2 hours. Past medical history is significant for poorly controlled hypertension, managed with multiple medications. His blood pressure is 188/87 mm Hg and pulse is 110/min. A non-contrast CT of the head is unremarkable and cerebrospinal fluid analysis is within normal limits, except for an RBC count of 5.58 x 106/mm3. Labetalol IV is administered. Which of the following medications should also be added to this patient’s management?
Q127
A 41-year-old African American man presents to his primary care physician a few months after being found to have a blood pressure of 152/95 mmHg. The patient denies any current symptoms, having any past medical history, or prior hospitalizations. He does not take any medications but takes one multivitamin daily. His blood pressures on three separate occasions have been 151/93 mmHg, 150/90 mmHg, and 155/97 mmHg. In today’s visit, his blood pressure is 149/91 mmHg despite exercise and dietary modifications. Physical examination is unremarkable. After extensive work-up he is started on appropriate monotherapy for his hypertension. Which of the following laboratory abnormalities may be found on follow-up testing?
Q128
A 56-year-old Caucasian male presents to the clinic to establish care. He has never seen a physician and denies any known medical problems. Physical examination is notable for central obesity, but the patient has regular heart and lung sounds. He has a blood pressure of 157/95 mm Hg and heart rate of 92/min. He follows up 2 weeks later, and his blood pressure continues to be elevated. At this time, you diagnose him with essential hypertension and decide to initiate antihypertensive therapy. Per the Joint National Committee 8 guidelines for treatment of high blood pressure, of the following combinations of drugs, which can be considered for first-line treatment of high blood pressure in the Caucasian population?
Q129
A 53-year old man presents for a well physical examination. He reports his diet is suboptimal, but otherwise reports a healthy lifestyle. He has no past medical history and only takes a multivitamin. He has a blood pressure of 116/74 mm Hg and a pulse of 76/min. On physical examination, he is in no acute distress, has no cardiac murmurs, and his lung sounds are clear to auscultation bilaterally. You order a lipid panel that returns as follows: LDL 203, HDL 37, TG 292. Of the following, which medication should be initiated?
Q130
A 65-year-old Caucasian man visits the nephrology outpatient clinic for a follow-up appointment. He was previously diagnosed with stage G3a chronic kidney disease (CKD) and albuminuria stage A2. He follows strict dietary recommendations and takes enalapril. He has a history of benign prostatic hyperplasia which has been complicated by urinary tract obstruction. His vitals are stable, and his blood pressure is within the recommended limits. His most recent laboratory studies are as follows:
Serum sodium 140 mEq/L
Serum potassium 5.8 mEq/L
Serum chloride 102 mEq/L
Serum phosphate 4.0 mg/dL
Hemoglobin 11.5 mg/dL
Albumin excretion rate (AER) 280 mg/day
Which of the following is the best strategy in the management of this patient?
Antihypertensives US Medical PG Practice Questions and MCQs
Question 121: A 45-year-old man presents to his primary care physician for a wellness checkup. He states that he feels fatigued at times but feels near his baseline. The patient smokes 1 pack of cigarettes per day, drinks alcohol occasionally, and has a past medical history of poorly controlled diabetes. His temperature is 98.6°F (37.0°C), blood pressure is 167/108 mmHg, pulse is 80/min, respirations are 10/min, and oxygen saturation is 98% on room air. Physical exam reveals an overweight man with a ruddy complexion. Bilateral gynecomastia is noted for which the patient inquires about cosmetic surgery as a treatment. Laboratory values are ordered as seen below.
Hemoglobin: 14 g/dL
Hematocrit: 42%
Leukocyte count: 6,500/mm³ with normal differential
Platelet count: 185,000/mm³
Serum:
Na+: 142 mEq/L
Cl-: 102 mEq/L
K+: 3.2 mEq/L
HCO3-: 31 mEq/L
BUN: 27 mg/dL
Glucose: 173 mg/dL
Creatinine: 1.5 mg/dL
Ca2+: 9.8 mg/dL
A CT scan demonstrates bilateral abnormal adrenal masses. What is the most appropriate initial treatment?
A. Measure aldosterone and renin levels
B. Amiloride
C. Spironolactone (Correct Answer)
D. Eplerenone
E. Bilateral adrenalectomy
Explanation: ***Spironolactone***
- The patient presents with **hypertension**, **hypokalemia** (K+ 3.2 mEq/L), **metabolic alkalosis** (HCO3- 31 mEq/L), **bilateral adrenal masses**, and **gynecomastia**, which are highly suggestive of **primary hyperaldosteronism** (Conn's syndrome), specifically **bilateral adrenal hyperplasia**.
- **Spironolactone** is an **aldosterone antagonist** that blocks mineralocorticoid receptors, thereby treating the hypertension and correcting the hypokalemia and metabolic alkalosis.
- It is the **first-line medical treatment** for **bilateral adrenal hyperplasia**, as surgery is typically reserved for unilateral adenomas.
- The existing gynecomastia noted in this patient is consistent with hyperaldosteronism and may be exacerbated by spironolactone's anti-androgenic effects, but this does not preclude its use as initial therapy.
*Measure aldosterone and renin levels*
- While measuring aldosterone and renin levels (aldosterone-to-renin ratio) is crucial for **diagnosing** primary hyperaldosteronism, this question asks for initial **treatment**.
- The clinical presentation (hypertension, hypokalemia, metabolic alkalosis, bilateral adrenal masses) already strongly suggests the diagnosis, and treatment would be initiated after diagnostic confirmation.
*Amiloride*
- **Amiloride** is a **potassium-sparing diuretic** that blocks epithelial sodium channels in the collecting duct, reducing sodium reabsorption and potassium excretion.
- While it can help manage hypokalemia and hypertension in hyperaldosteronism, it is **less effective** than spironolactone in directly antagonizing aldosterone's effects and is considered a second-line agent.
*Eplerenone*
- **Eplerenone** is a **selective aldosterone antagonist** with fewer anti-androgenic side effects compared to spironolactone (less gynecomastia, erectile dysfunction).
- While equally effective for treating hyperaldosteronism, **spironolactone** remains the first-line choice due to its established efficacy, longer track record, and lower cost.
- Eplerenone may be preferred in patients who develop intolerable anti-androgenic side effects from spironolactone.
*Bilateral adrenalectomy*
- **Bilateral adrenalectomy** would result in permanent adrenal insufficiency requiring lifelong glucocorticoid and mineralocorticoid replacement.
- Surgery is typically reserved for **unilateral aldosterone-producing adenomas** (after lateralization studies) where unilateral adrenalectomy can be curative.
- For bilateral adrenal hyperplasia, **medical management** with mineralocorticoid receptor antagonists is the preferred approach.
Question 122: A 47-year-old woman comes to the physician for a follow-up examination. She has type 1 diabetes mellitus, end-stage renal disease, and was recently started on erythropoietin for anemia. Her last hemodialysis session was yesterday. Current medications also include insulin, calcitriol, and sevelamer. She appears well. Her pulse is 68/min and regular, respirations are 12/min, and blood pressure is 169/108 mm Hg. Her blood pressure was normal at previous visits. Examination shows normal heart sounds. There are no carotid, femoral, or abdominal bruits. The lungs are clear to auscultation. Laboratory studies show a hemoglobin concentration of 12 g/dL, a serum creatinine concentration of 3.4 mg/dL, and BUN of 20 mg/dL. Which of the following is the most likely cause of this patient's hypertension?
A. Autonomic neuropathy
B. Erythropoietin therapy (Correct Answer)
C. Hypervolemia
D. Hypoglycemia
E. Calcitriol therapy
Explanation: ***Erythropoietin therapy***
- **Erythropoietin (EPO)** can cause or exacerbate hypertension, particularly in patients with chronic kidney disease, by increasing peripheral vascular resistance and vasoconstriction.
- The patient was recently started on erythropoietin, and her blood pressure was normal at previous visits, suggesting a direct link.
*Autonomic neuropathy*
- While common in **diabetic patients**, autonomic neuropathy typically leads to **orthostatic hypotension**, not an acute elevation in systolic and diastolic blood pressure.
- It would not explain the sudden onset of hypertension in a patient whose blood pressure was previously normal.
*Hypervolemia*
- The patient had hemodialysis yesterday, which generally removes excess fluid, making **hypervolemia** less likely as the primary cause of acute hypertension.
- Clinical signs of hypervolemia (e.g., pulmonary edema, JVD) are absent, as the lungs are clear and she appears well.
*Hypoglycemia*
- **Hypoglycemia** can cause sympathetic activation and lead to a temporary increase in blood pressure, but it is usually associated with other symptoms like palpitations, sweating, and tremor.
- It would also not explain sustained hypertension, and there is no indication of hypoglycemia in the patient's presentation.
*Calcitriol therapy*
- **Calcitriol**, a form of vitamin D, is used to manage secondary hyperparathyroidism in ESRD but is not directly associated with causing **acute hypertension**.
- Its effects primarily relate to calcium and phosphorus metabolism, not direct blood pressure regulation.
Question 123: A 35-year-old woman presents to the emergency department with swelling of her face and abdominal pain. She states she was outside doing yard work when her symptoms began. The patient has a past medical history of recently diagnosed diabetes and hypertension. Her current medications include lisinopril, metformin, and glipizide. Her temperature is 99.5°F (37.5°C), blood pressure is 149/95 mmHg, pulse is 90/min, respirations are 15/min, and oxygen saturation is 99% on room air. On physical exam, the patient's cardiac and pulmonary exam are within normal limits. Dermatologic exam reveals edema of her hands, lips, and eyelids. There is mild laryngeal edema; however, the patient is speaking clearly and maintaining her airway. Which of the following is appropriate long-term management of this patient?
A. Danazol
B. Discontinue lisinopril (Correct Answer)
C. Prednisone
D. Ecallantide
E. Fresh frozen plasma
Explanation: ***Discontinue lisinopril***
- The patient's presentation with **facial edema**, **abdominal pain**, and mild **laryngeal edema** after starting lisinopril is highly suggestive of **angioedema induced by ACE inhibitors**. Discontinuing the causative agent is the primary long-term management.
- **ACE inhibitors** like lisinopril can inhibit the breakdown of **bradykinin**, leading to its accumulation and subsequent vascular leakage and angioedema. This is a common and potentially life-threatening side effect.
*Danazol*
- **Danazol** is an **attenuated androgen** sometimes used for long-term prophylaxis in **hereditary angioedema** to increase C1 esterase inhibitor levels. However, it is not indicated for ACE inhibitor-induced angioedema, which is not due to a C1-INH deficiency.
- Its use is associated with significant **androgenic side effects**, making it unsuitable for this patient's condition.
*Prednisone*
- **Prednisone**, a corticosteroid, is typically used to manage **allergic reactions** and reduce inflammation. However, **ACE inhibitor-induced angioedema** is a **bradykinin-mediated process**, not histamine-mediated, and thus does not respond to corticosteroids or antihistamines.
- Administering prednisone would not address the underlying cause of bradykinin accumulation and would expose the patient to unnecessary side effects.
*Ecallantide*
- **Ecallantide** is a **kallikrein inhibitor** used for the acute treatment of hereditary angioedema. It works by blocking the enzyme kallikrein, which is involved in bradykinin production.
- While effective in acute episodes of hereditary angioedema, it is not a long-term management strategy for ACE inhibitor-induced angioedema, particularly after the acute phase has resolved by removing the offending agent.
*Fresh frozen plasma*
- **Fresh frozen plasma (FFP)** contains all clotting factors, including C1 esterase inhibitor, and is used in certain severe cases of **hereditary angioedema** as an acute treatment, especially when C1-INH concentrate is unavailable.
- FFP is not indicated for long-term management of ACE inhibitor-induced angioedema, as the underlying problem is not a deficiency of C1 esterase inhibitor but rather bradykinin accumulation due to ACE inhibition.
Question 124: A 64-year-old gentleman with hypertension is started on a new diuretic medication by his primary care physician because of poor blood pressure control on his previous regimen. Before starting, he is warned by his physician that the new medication may have side effects including hypokalemia and metabolic alkalosis. Furthermore it may cause alterations in his metabolites such as hyperglycemia, hyperlipidemia, hyperuricemia, and hypercalcemia. What is the mechanism of the class of diuretic most likely being recommended by the physician?
A. Aldosterone receptor inhibitor
B. NKCC inhibitor in loop of Henle
C. NCC inhibitor in distal tubule (Correct Answer)
D. ENaC inhibitor in collecting duct
E. Osmotic diuresis
Explanation: ***NCC inhibitor in distal tubule***
- The side effects described (hypokalemia, metabolic alkalosis, hyperglycemia, hyperlipidemia, hyperuricemia, and hypercalcemia) are characteristic of **thiazide diuretics**, which work by inhibiting the **Na-Cl cotransporter (NCC)** in the distal convoluted tubule.
- This inhibition leads to increased sodium and water excretion, while also diminishing calcium excretion, contributing to hypercalcemia.
*Aldosterone receptor inhibitor*
- **Aldosterone antagonists** (e.g., spironolactone, eplerenone) primarily cause **hyperkalemia** and **metabolic acidosis**, which is the opposite of what is described in the clinical scenario.
- They also do not typically cause hyperglycemia, hyperlipidemia, or hyperuricemia.
*NKCC inhibitor in loop of Henle*
- **Loop diuretics** (e.g., furosemide, bumetanide) inhibit the **Na-K-2Cl cotransporter (NKCC)** in the thick ascending limb of the loop of Henle. While they cause hypokalemia and metabolic alkalosis, they generally lead to **hypocalcemia** due to increased calcium excretion, not hypercalcemia.
- They are also not typically associated with chronic hyperglycemia or hyperlipidemia to the same extent as thiazides.
*ENaC inhibitor in collecting duct*
- **ENaC inhibitors**, also known as potassium-sparing diuretics (e.g., amiloride, triamterene), block the epithelial sodium channel in the collecting duct.
- Their primary side effect is **hyperkalemia**, which contradicts the described hypokalemia.
*Osmotic diuresis*
- **Osmotic diuretics** (e.g., mannitol) act by increasing the osmolality of the tubular fluid, leading to reduced water reabsorption.
- Their side effect profile is different, often involving fluid and electrolyte imbalances but not typically the specific metabolic alterations mentioned (hyperglycemia, hyperlipidemia, hyperuricemia, hypercalcemia) in the context of long-term hypertension management.
Question 125: A 68-year-old man presents to the clinic for a regular health checkup. He is hypertensive and was diagnosed with congestive heart failure last year. He has hyperlipidemia but does not take any medication for it. Although he takes his antihypertensive medications regularly, his blood pressure recordings at home tend to range between 150/98 and 160/90 mm Hg. Today, his blood pressure is 147/96 mm Hg. The doctor decides to add indapamide to his medication list and asks the patient to follow up within 2 weeks. The patient is compliant with the medication. He comes back to the physician in just one week complaining of muscle cramping and weakness. Which of the following is the most likely cause of his symptoms?
A. Hypoglycemia
B. Hypokalemia (Correct Answer)
C. Hyperuricemia
D. Hyperlipidemia
E. Hypocalcemia
Explanation: ***Hypokalemia***
- Indapamide is a **thiazide-like diuretic** that can cause **potassium wasting**, leading to hypokalemia.
- **Muscle cramping** and **weakness** are classic symptoms of hypokalemia, as potassium is crucial for normal muscle function.
*Hypoglycemia*
- Hypoglycemia is characterized by symptoms such as **shakiness**, **sweating**, **dizziness**, and **confusion**, which are not reported here.
- There is no indication of diabetes or medications that would significantly drop blood glucose in this patient.
*Hyperuricemia*
- Hyperuricemia can lead to **gout**, presenting with acute, severe joint pain and inflammation, typically in the big toe.
- While indapamide can cause hyperuricemia, it generally does not cause muscle cramping and weakness as its primary manifestation.
*Hyperlipidemia*
- Hyperlipidemia itself is typically **asymptomatic** and only causes symptoms when it leads to complications like atherosclerosis.
- This condition does not directly cause acute muscle cramping and weakness.
*Hypocalcemia*
- Hypocalcemia can cause muscle cramps and spasms (tetany), but it often presents with additional symptoms like **paresthesias**, **Chvostek's sign**, or **Trousseau's sign**.
- Indapamide is more likely to cause hypokalemia than hypocalcemia, and direct evidence for a calcium imbalance is not provided.
Question 126: A 58-year-old man presents with a sudden-onset severe headache and vomiting for the past 2 hours. Past medical history is significant for poorly controlled hypertension, managed with multiple medications. His blood pressure is 188/87 mm Hg and pulse is 110/min. A non-contrast CT of the head is unremarkable and cerebrospinal fluid analysis is within normal limits, except for an RBC count of 5.58 x 106/mm3. Labetalol IV is administered. Which of the following medications should also be added to this patient’s management?
A. Nifedipine
B. Ecosprin
C. Nimodipine (Correct Answer)
D. Furosemide
E. Verapamil
Explanation: ***Nimodipine***
- This patient presents with symptoms suggestive of a **subarachnoid hemorrhage (SAH)**, including a sudden severe headache, vomiting, and **xanthochromia** (high RBC count in CSF) despite a normal CT. **Nimodipine** is a calcium channel blocker specifically used in SAH to prevent **cerebral vasospasm**, a common and devastating complication.
- Cerebral vasospasm can lead to **delayed cerebral ischemia** and further neurological deficits, and nimodipine has been shown to improve neurological outcomes.
*Nifedipine*
- **Nifedipine** is a dihydropyridine calcium channel blocker used for hypertension but is not indicated for the prevention of cerebral vasospasm in SAH.
- Its use in SAH could potentially lead to systemic hypotension without the specific cerebrovascular benefits of nimodipine, potentially worsening cerebral perfusion.
*Ecosprin*
- **Ecosprin (aspirin)** is an antiplatelet agent used for thrombosis prevention but is **contraindicated** in acute SAH due to its antiplatelet effect, which could worsen bleeding.
- There is no indication for antiplatelet therapy in the immediate management of SAH.
*Furosemide*
- **Furosemide** is a loop diuretic used to manage fluid overload, hypertension, or cerebral edema.
- While hypertension is partially present, furosemide is not directly indicated for the management or prevention of complications of SAH, and its diuretic effect could lead to dehydration, which may exacerbate hypovolemia.
*Verapamil*
- **Verapamil** is a non-dihydropyridine calcium channel blocker primarily used for arrhythmias and hypertension.
- It is not specifically indicated or shown to be effective in preventing cerebral vasospasm after SAH, unlike nimodipine.
Question 127: A 41-year-old African American man presents to his primary care physician a few months after being found to have a blood pressure of 152/95 mmHg. The patient denies any current symptoms, having any past medical history, or prior hospitalizations. He does not take any medications but takes one multivitamin daily. His blood pressures on three separate occasions have been 151/93 mmHg, 150/90 mmHg, and 155/97 mmHg. In today’s visit, his blood pressure is 149/91 mmHg despite exercise and dietary modifications. Physical examination is unremarkable. After extensive work-up he is started on appropriate monotherapy for his hypertension. Which of the following laboratory abnormalities may be found on follow-up testing?
A. Hyperkalemia
B. Hypermagnesemia
C. Hypolipidemia
D. Hypercalcemia (Correct Answer)
E. Hypouricemia
Explanation: **Hypercalcemia**
- This African American patient with stage 2 hypertension unresponsive to lifestyle modifications requires pharmacologic therapy.
- **First-line options** for African American patients include **thiazide diuretics** or **calcium channel blockers** (per ACC/AHA guidelines).
- Given the question asks about hypercalcemia, the appropriate monotherapy is a **thiazide diuretic** (e.g., chlorthalidone, hydrochlorothiazide).
- Thiazide diuretics **inhibit calcium excretion** in the distal convoluted tubule, leading to increased calcium reabsorption and potential **hypercalcemia**.
- This is a well-known side effect that requires monitoring during thiazide therapy.
*Hyperkalemia*
- **Thiazide diuretics** cause **hypokalemia** (low potassium), not hyperkalemia, by increasing potassium excretion in the distal tubule.
- Hyperkalemia is associated with **potassium-sparing diuretics** (spironolactone, amiloride), **ACE inhibitors**, or **ARBs**.
*Hypermagnesemia*
- **Thiazide diuretics** increase urinary magnesium excretion, potentially causing **hypomagnesemia**, not hypermagnesemia.
- Hypermagnesemia is rare and typically seen with renal failure or excessive magnesium supplementation.
*Hypolipidemia*
- **Thiazide diuretics** can cause **mild dyslipidemia** (increased LDL cholesterol and triglycerides), not hypolipidemia.
- Hypolipidemia (abnormally low lipid levels) is not a recognized side effect of antihypertensive therapy.
*Hypouricemia*
- **Thiazide diuretics** decrease uric acid secretion in the proximal tubule, leading to **hyperuricemia** and potential gout precipitation.
- Hypouricemia would not be expected with thiazide therapy.
Question 128: A 56-year-old Caucasian male presents to the clinic to establish care. He has never seen a physician and denies any known medical problems. Physical examination is notable for central obesity, but the patient has regular heart and lung sounds. He has a blood pressure of 157/95 mm Hg and heart rate of 92/min. He follows up 2 weeks later, and his blood pressure continues to be elevated. At this time, you diagnose him with essential hypertension and decide to initiate antihypertensive therapy. Per the Joint National Committee 8 guidelines for treatment of high blood pressure, of the following combinations of drugs, which can be considered for first-line treatment of high blood pressure in the Caucasian population?
A. ACE inhibitor, ARB, CCB, or thiazide (Correct Answer)
B. ACE inhibitor, angiotensin receptor blocker (ARB), beta-blocker (BB), or thiazide
C. ACE inhibitor, ARB, CCB, or loop diuretic
D. ACE inhibitor, ARB, alpha-blocker, or loop diuretic
E. ACE inhibitor, ARB, alpha-blocker, or direct vasodilator
Explanation: **ACE inhibitor, ARB, CCB, or thiazide**
- The **JNC 8 guidelines** recommend **ACE inhibitors**, **ARBs**, **calcium channel blockers (CCBs)**, and **thiazide diuretics** as first-line agents for essential hypertension in the general non-Black population.
- These drug classes have demonstrated efficacy in reducing cardiovascular events and are generally well-tolerated.
*ACE inhibitor, angiotensin receptor blocker (ARB), beta-blocker (BB), or thiazide*
- While **ACE inhibitors**, **ARBs**, and **thiazides** are first-line, **beta-blockers** are generally not considered first-line for uncomplicated hypertension unless there are specific compelling indications (e.g., post-MI, heart failure).
- **Beta-blockers** are less effective than other first-line agents in preventing stroke in the elderly and may have more side effects in some populations.
*ACE inhibitor, ARB, CCB or loop diuretic*
- **ACE inhibitors**, **ARBs**, and **CCBs** are first-line options, but **loop diuretics** are typically reserved for patients with fluid overload or chronic kidney disease, not for initial management of essential hypertension.
- **Loop diuretics** have a shorter duration of action and a greater electrolyte-wasting effect compared to thiazide diuretics, making them less suitable for long-term monotherapy.
*ACE inhibitor, ARB, alpha-blocker, or loop diuretic*
- **Alpha-blockers** and **loop diuretics** are not considered first-line agents for essential hypertension. **Alpha-blockers** are typically used for benign prostatic hyperplasia or as add-on therapy for resistant hypertension.
- **Alpha-blockers** can cause significant orthostatic hypotension, particularly with the first dose, and have not shown the same cardiovascular protective benefits as true first-line agents.
*ACE inhibitor, ARB, alpha-blocker, or direct vasodilator*
- **Alpha-blockers** and **direct vasodilators** (e.g., hydralazine, minoxidil) are not first-line treatments for essential hypertension.
- **Direct vasodilators** are potent but often cause reflex tachycardia and fluid retention, requiring co-administration with other agents, and are typically reserved for severe or resistant hypertension.
Question 129: A 53-year old man presents for a well physical examination. He reports his diet is suboptimal, but otherwise reports a healthy lifestyle. He has no past medical history and only takes a multivitamin. He has a blood pressure of 116/74 mm Hg and a pulse of 76/min. On physical examination, he is in no acute distress, has no cardiac murmurs, and his lung sounds are clear to auscultation bilaterally. You order a lipid panel that returns as follows: LDL 203, HDL 37, TG 292. Of the following, which medication should be initiated?
A. Ezetimibe 10 mg daily
B. Colesevelam 3.75 grams daily
C. Atorvastatin 40 mg daily (Correct Answer)
D. Fenofibrate 145 mg daily
E. Simvastatin 10 mg daily
Explanation: ***Atorvastatin 40 mg***
- This patient has a **very high LDL level of 203 mg/dL** and is over 40 years old, placing him in a high-risk group that warrants initiation of a **high-intensity statin** for primary prevention of cardiovascular disease.
- **Atorvastatin 40 mg** is a high-intensity statin known to reduce LDL cholesterol by 50% or more, which is appropriate for this patient's elevated risk.
*Ezetimibe 10 mg daily*
- **Ezetimibe** works by inhibiting cholesterol absorption in the small intestine and is typically used as an add-on therapy for patients who do not achieve their LDL goals with statins alone, or for those who are statin-intolerant.
- It is not a first-line monotherapy for a patient with such significantly elevated LDL cholesterol.
*Colesevelam 3.75 grams daily*
- **Colesevelam** is a bile acid sequestrant that lowers LDL by increasing its fecal excretion; however, it has a more modest LDL-lowering effect compared to statins and can sometimes increase triglycerides.
- It is not the most effective or appropriate first-line agent, especially given the patient's existing elevated triglyceride levels.
*Fenofibrate 145 mg daily*
- **Fenofibrate** is primarily used to lower **triglycerides** and can mildly raise HDL, but it has minimal effect on LDL cholesterol.
- While the patient has elevated triglycerides, his primary and most significant lipid abnormality requiring immediate intervention for cardiovascular risk reduction is his severely elevated LDL.
*Simvastatin 10 mg daily*
- **Simvastatin 10 mg** is a **low-intensity statin** dose (typical range: 10-20 mg), which is not sufficient for a patient with an LDL of 203 mg/dL and high cardiovascular risk.
- Guidelines recommend a **high-intensity statin** like atorvastatin 40-80 mg or rosuvastatin 20-40 mg for such elevated LDL levels.
Question 130: A 65-year-old Caucasian man visits the nephrology outpatient clinic for a follow-up appointment. He was previously diagnosed with stage G3a chronic kidney disease (CKD) and albuminuria stage A2. He follows strict dietary recommendations and takes enalapril. He has a history of benign prostatic hyperplasia which has been complicated by urinary tract obstruction. His vitals are stable, and his blood pressure is within the recommended limits. His most recent laboratory studies are as follows:
Serum sodium 140 mEq/L
Serum potassium 5.8 mEq/L
Serum chloride 102 mEq/L
Serum phosphate 4.0 mg/dL
Hemoglobin 11.5 mg/dL
Albumin excretion rate (AER) 280 mg/day
Which of the following is the best strategy in the management of this patient?
A. Observation
B. Addition of furosemide
C. Addition of patiromer (Correct Answer)
D. Addition of sevelamer
E. Removal of enalapril
Explanation: ***Addition of patiromer***
- The patient has **hyperkalemia** (serum potassium 5.8 mEq/L) which is exacerbated by his enalapril use and CKD; **patiromer** is a potassium binder that can effectively lower serum potassium without necessitating discontinuation of essential medications like ACE inhibitors.
- Patiromer is a good choice for chronic hyperkalemia in patients with **CKD** who require drugs that can increase potassium, such as **ACE inhibitors**, helping to maintain the benefits of these renoprotective agents.
*Observation*
- The patient's **serum potassium is elevated at 5.8 mEq/L**, which is a potentially dangerous level requiring intervention, not just observation.
- Hyperkalemia can lead to **life-threatening cardiac arrhythmias**, necessitating active management rather than a wait-and-see approach.
*Addition of furosemide*
- While furosemide can promote potassium excretion, its primary role is fluid removal and relief of congestion, and it may not be sufficient to address significant hyperkalemia in a patient on an **ACE inhibitor** with CKD.
- Furosemide would not directly counteract the potassium-retaining effect of **enalapril** as effectively as a potassium binder would, especially in the context of controlled blood pressure and no overt fluid overload.
*Addition of sevelamer*
- **Sevelamer** is a phosphate binder primarily used to manage **hyperphosphatemia** in CKD patients, which this patient does not have (serum phosphate 4.0 mg/dL is within normal limits).
- Its mechanism of action does not involve **potassium binding** or excretion, making it ineffective for the patient's hyperkalemia.
*Removal of enalapril*
- **Enalapril** is crucial for its **renoprotective effects**, including reducing proteinuria (AER 280 mg/day) and controlling blood pressure in CKD patients.
- Discontinuing enalapril would remove these benefits and could worsen kidney disease progression and proteinuria, while there are other strategies (like **patiromer**) to manage the side effect of hyperkalemia.